|
1
|
Adisa JO, Egbujo EC, Ibrahim B, Musa B and
Madukwe J: Expression of some selected cytokeratins and Ki67
protein in prostatic tumor: Can these be used as tumor markers. Pan
Afr Med J. 20:462015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qi JL, Wang LJ, Zhou MG, Liu YN, Liu JM,
Liu SW, Zeng XY and Yin P: Disease burden of prostate cancer among
men in China from 1990 to 2013. Zhonghua Liu Xing Bing Xue Za Zhi.
37:778–782. 2016.In Chinese. PubMed/NCBI
|
|
4
|
Pound CR, Partin AW, Eisenberger MA, Chan
DW, Pearson JD and Walsh PC: Natural history of progression after
PSA elevation following radical prostatectomy. JAMA. 281:1591–1597.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Logothetis CJ and Lin SH: Osteoblasts in
prostate cancer metastasis to bone. Nat Rev Cancer. 5:21–28. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kosuda S, Yoshimura I, Aizawa T, Koizumi
K, Akakura K, Kuyama J, Ichihara K, Yonese J, Koizumi M, Nakashima
J, et al: Can initial prostate specific antigen determinations
eliminate the need for bone scans in patients with newly diagnosed
prostate carcinoma? A multicenter retrospective study in Japan.
Cancer. 94:964–972. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tanaka N, Fujimoto K, Shinkai T, Nakai Y,
Kuwada M, Anai S, Miyake M, Hirayama A, Hasegawa M and Hirao Y:
Bone scan can be spared in asymptomatic prostate cancer patients
with PSA of <=20 ng/ml and Gleason score of <=6 at the
initial stage of diagnosis. Jpn J Clin Oncol. 41:1209–1213. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lilleby W and Fosså SD: Chemotherapy in
metastatic renal cell cancer. World J Urol. 23:175–179. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Todorova K, Metodiev MV, Metodieva G,
Zasheva D, Mincheff M and Hayrabedyan S: miR-204 is dysregulated in
metastatic prostate cancer in vitro. Mol Carcinog. 55:131–147.
2016. View
Article : Google Scholar
|
|
10
|
Siu MK, Tsai YC, Chang YS, Yin JJ, Suau F,
Chen WY and Liu YN: Transforming growth factor-β promotes prostate
bone metastasis through induction of microRNA-96 and activation of
the mTOR pathway. Oncogene. 34:4767–4776. 2015. View Article : Google Scholar
|
|
11
|
Browne G, Taipaleenmäki H, Stein GS, Stein
JL and Lian JB: MicroRNAs in the control of metastatic bone
disease. Trends Endocrinol Metab. 25:320–327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abba M, Patil N, Leupold JH and Allgayer
H: MicroRNAs - from metastasis prediction to metastasis prevention?
Mol Cell Oncol. 3:e10743362015. View Article : Google Scholar
|
|
13
|
Wang R, Xu J, Mabjeesh N, Zhu G, Zhou J,
Amin M, He D, Marshall FF, Zhau HE and Chung LW: PrLZ is expressed
in normal prostate development and in human prostate cancer
progression. Clin Cancer Res. 13:6040–6048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li L, Zhang D, Zhang L, Zhu G, Sun Y, Wu
K, Wang X and He D: PrLZ expression is associated with the
progression of prostate cancer LNCaP cells. Mol Carcinog.
48:432–440. 2009. View
Article : Google Scholar
|
|
15
|
Li L, Xie H, Liang L, Gao Y, Zhang D, Fang
L, Lee SO, Luo J, Chen X, Wang X, et al: Increased PrLZ-mediated
androgen receptor transactivation promotes prostate cancer growth
at castration-resistant stage. Carcinogenesis. 34:257–267. 2013.
View Article : Google Scholar :
|
|
16
|
Upile T, Jerjes W, Radhi H, Al-Khawalde M,
Kafas P, Nouraei S and Sudhoff H: Vascular mimicry in cultured head
and neck tumour cell lines. Head Neck Oncol. 3:552011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deep G, Jain AK, Ramteke A, Ting H,
Vijendra KC, Gangar SC, Agarwal C and Agarwal R: SNAI1 is critical
for the aggressiveness of prostate cancer cells with low
E-cadherin. Mol Cancer. 13:372014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Keller ET, Dai J, Escara-Wilke J, Hall CL,
Ignatoski K, Taichman RS and Keller J: New trends in the treatment
of bone metastasis. J Cell Biochem. 102:1095–1102. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weidle UH, Birzele F, Kollmorgen G and
Rüger R: Molecular mechanisms of bone metastasis. Cancer Genomics
Proteomics. 13:1–12. 2016.
|
|
20
|
Singh R, Ramasubramanian B, Kanji S,
Chakraborty AR, Haque SJ and Chakravarti A: Circulating microRNAs
in cancer: Hope or hype? Cancer Lett. 381:113–121. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
White NM, Fatoohi E, Metias M, Jung K,
Stephan C and Yousef GM: Metastamirs: A stepping stone towards
improved cancer management. Nat Rev Clin Oncol. 8:75–84. 2011.
View Article : Google Scholar
|
|
22
|
Ell B and Kang Y: MicroRNAs as regulators
of bone homeostasis and bone metastasis. Bonekey Rep. 3:5492014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen SP, Liu BX, Xu J, Pei XF, Liao YJ,
Yuan F and Zheng F: MiR-449a suppresses the epithelial-mesenchymal
transition and metastasis of hepatocellular carcinoma by multiple
targets. BMC Cancer. 15:7062015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luo W, Huang B, Li Z, Li H, Sun L, Zhang
Q, Qiu X and Wang E: MicroRNA-449a is downregulated in non-small
cell lung cancer and inhibits migration and invasion by targeting
c-Met. PLoS One. 8:e647592013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Q, Peng J, Li X, Leng A and Liu T:
miR-449a targets Flot2 and inhibits gastric cancer invasion by
inhibiting TGF-β-mediated EMT. Diagn Pathol. 10:2022015. View Article : Google Scholar
|
|
26
|
Noonan EJ, Place RF, Pookot D, Basak S,
Whitson JM, Hirata H, Giardina C and Dahiya R: miR-449a targets
HDAC-1 and induces growth arrest in prostate cancer. Oncogene.
28:1714–1724. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mao A, Zhao Q, Zhou X, Sun C, Si J, Zhou
R, Gan L and Zhang H: MicroRNA-449a enhances radiosensitivity by
downregulation of c-Myc in prostate cancer cells. Sci Rep.
6:273462016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Graff JR and Zimmer SG: Translational
control and metastatic progression: Enhanced activity of the mRNA
cap-binding protein eIF-4E selectively enhances translation of
metastasis-related mRNAs. Clin Exp Metastasis. 20:265–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kelly T, Suva LJ, Huang Y, Macleod V, Miao
HQ, Walker RC and Sanderson RD: Expression of heparanase by primary
breast tumors promotes bone resorption in the absence of detectable
bone metastases. Cancer Res. 65:5778–5784. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miyamoto N, Yamamoto H, Taniguchi H,
Miyamoto C, Oki M, Adachi Y, Imai K and Shinomura Y: Differential
expression of angiogenesis-related genes in human gastric cancers
with and those without high-frequency microsatellite instability.
Cancer Lett. 254:42–53. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Perlikos F, Harrington KJ and Syrigos KN:
Key molecular mechanisms in lung cancer invasion and metastasis: A
comprehensive review. Crit Rev Oncol Hematol. 87:1–11. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sandbothe M, Buurman R, Reich N, Greiwe L,
Vajen B, Gürlevik E, Schäffer V, Eilers M, Kühnel F, Vaquero A, et
al: The microRNA-449 family inhibits TGF-β-mediated liver cancer
cell migration by targeting SOX4. J Hepatol. 66:1012–1021. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang H, Wang J, Pang B, Liang RX, Li S,
Huang PT, Wang R, Chung LW, Zhau HE, Huang C, et al: PC-1/PrLZ
contributes to malignant progression in prostate cancer. Cancer
Res. 67:8906–8913. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nakazawa M and Kyprianou N:
Epithelial-mesenchymal-transition regulators in prostate cancer:
Androgens and beyond. J Steroid Biochem Mol Biol. 166:84–90. 2017.
View Article : Google Scholar
|
|
35
|
Diepenbruck M and Christofori G:
Epithelial-mesenchymal transition (EMT) and metastasis: Yes, no,
maybe? Curr Opin Cell Biol. 43:7–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim EK, Choi EJ and Debnath T: Role of
phytochemicals in the inhibition of epithelial-mesenchymal
transition in cancer metastasis. Food Funct. 7:3677–3685. 2016.
View Article : Google Scholar : PubMed/NCBI
|
